Stada postpones IPO amid ongoing market volatility

8th Apr 2025 12:59

(Sharecast News) - German pharma firm Stada is the latest in a string of private companies that have postponed their plans to go public due to ongoing market volatility and geopolitical uncertainty.

In an announcement on Tuesday, the firm said it was evaluating a new date for its initial public offering on the Frankfurt stock exchange.

While markets in Europe were trading firmly higher on Tuesday, stocks across the continent had plummeted to a 15-month low on Monday as investors reacted to the latest development in an escalating trade war between the US and its trading partners.

The Stoxx Europe 600 benchmark had dropped nearly 12% since the Trump administration announced its sweeping trade tariffs on US imports late on 2 April.

Stada, which made more than €4bn in sales in 2024 and €886m in EBITDA, operates in the consumer healthcare, specialty pharmaceuticals and generic drugs markets. According to reports, it was targeting a valuation of around €10bn and planned to raise €1.5bn at an IPO, marking one of the largest IPOs in Europe this year.

The company, backed by private equity firms Bain Capital and Cinven, had revealed its intention to go public in January, though reports last month suggested that it could shelves plans due to market uncertainty.

Tuesday's IPO postponement follows similar announcements by Klarna and StubHub, who both delayed their IPO investor events due to current volatility.